RNTX vs XYL · $80.6M cap vs P/E 27, rev $4.46B
Rein Therapeutics Inc (RNTX) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Rein Therapeutics Inc (RNTX) is a biotechnology company listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported RNTX revenue for 2026-06-30 was $0. Net income was -$12.2M. RNTX currently screens at market cap $80.6M.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
RNTX currently screens at market cap $80.6M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the RNTX and XYL stock pages for the full models.
Not investment advice.